Status:
COMPLETED
A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients
Lead Sponsor:
TWi Biotechnology, Inc.
Conditions:
Inherited Epidermolysis Bullosa
Eligibility:
All Genders
2+ years
Phase:
PHASE2
Brief Summary
Inherited epidermolysis bullosa (EB) is a genetic skin disorder characterized by skin fragility and recurrent blister formation. More and more evidence has suggested that the skin lesions initially ca...
Eligibility Criteria
Inclusion
- Subject is at least 2 years of age.
- Subject has a clinical diagnosis of EB.
- Subject has a laboratory confirmed diagnosis of inherited EB based on electron microscopy and/or immunofluorescence antigenic mapping.
- Subject has two comparable areas with 1% - 5% BSA each. These two areas could be on any body surface except the face, scalp, groin, palms and soles. Percentage BSA of the designated areas within subject should be the same. Comparable areas are defined as having similar lesion (i.e., blisters, erosions, erythema and crusts) history and current lesion status by investigator's judgement on each area at Screening Visit (Visit 1) and Day 1 (Visit 2).
- Is male, or is female and meets all the following criteria:
- Not breastfeeding
- If of childbearing potential (defined as non-post-hysterectomy or non-post-menopausal \[≥50 years of age and amenorrheic for at least 1 year\]), must have a negative pregnancy test result at Visit 1, and must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.
- Is able to read, understand, and sign the Informed Consent Form (ICF), answer the study questionnaires, communicate with the investigator, and understand and comply with protocol requirements, OR Informed consent received from subject's parents/caregiver or legal guardian (when subject \< 20 years).
Exclusion
- Subject has a current malignancy, or a history of treatment for a malignancy within two years.
- Systemic infections.
- Subjects who are pregnant, lactating, or planning a pregnancy during the study.
- History of allergy or hypersensitivity to any component of study medication.
- Any other significant diseases, conditions, or laboratory values which, in the opinion of the investigator, might make participation not in the subject's best interest or confound the interpretation of study results.
- Any prior use of approved or investigational biologic anti-inflammatory therapy within 6 months prior to screening, including but not limited to: anakinra, rilonacept, canakinumab, etanercept, adalimumab, infliximab, rituximab, certolizumab, golimumab, tocilizumab, bertilimumab, or abatacept.
- Use of non-steroid immunosuppressants including but not limited to azathioprine, mycophenolate, cyclophosphamide, chlorambucil, methotrexate, tacrolimus, or cyclosporine in the 2 weeks prior to screening.
- Has been treated with gentamicin within 90 days prior to screening (Note: products containing gentamicin used on eyes are allowed).
- Has been treated with minocycline, oxytetracycline, tetracycline or doxycycline within 7 days prior to screening.
- Subjects has used any topical allantoin ≥ 3% within 30 days prior to screening.
- Has been treated systemic steroid within 30 days prior to screening.
- Prior treatment with any investigational therapy within 30 days prior to screening.
- Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site.
- Is employed by sponsor (i.e., is an employee, temporary contract worker, or designee responsible for the conduct of the study).
Key Trial Info
Start Date :
October 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 9 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03468322
Start Date
October 20 2018
End Date
April 9 2019
Last Update
April 16 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mackay Memorial Hospital
Hsinchu, Taiwan
2
National Cheng Kung University Hospital
Tainan, Taiwan